Source-grounded facts extracted from ORAMED PHARMACEUTICALS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ORAMED PHARMACEUTICALS INC. completed a disposition involving Lifeward Ltd. for Lifeward issuing to the Company a number of ordinary shares, no par value per share, of Lifeward, and pre-funded warrants to purchase the number of Lifeward Ord (closed 2026-03-25).
“On March 25, 2026, Lifeward completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement.”
ORAMED PHARMACEUTICALS INC. entered into Warrant Agreement with Scilex Holding Company (effective 2026-02-19).
“On February 19, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into a Warrant Agreement (the “Warrant Agreement”) with Scilex Holding Company (“Scilex”).”
ORAMED PHARMACEUTICALS INC. entered into Share Purchase Agreement with Lifeward Ltd. (effective 2026-01-12).
“On January 12, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into that certain Share Purchase Agreement (“Share Purchase Agreement”), by and among the Company, Lifeward Ltd. (“Lifeward”) and Oratech Pharma, Inc., the Company’s wholly-owned subsidiary (“Oratech”).”
Avraham Gabay was appointed as Chief Financial Officer, Treasurer and Secretary at ORAMED PHARMACEUTICALS INC..
“On June 6, 2024, Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Avraham Gabay to serve as the Chief Financial Officer, Treasurer and Secretary of the Company, effective as of June 18, 2024.”
David Silberman resigned as Chief Financial Officer, Treasurer and Secretary at ORAMED PHARMACEUTICALS INC..
“On May 10, 2024, David Silberman, the Chief Financial Officer, Treasurer and Secretary (the “CFO”) of Oramed Pharmaceuticals Inc. (the “Company”), resigned from his positions with the Company for personal reasons, effective as of July 12, 2024.”
Yehuda Reznick was appointed as director at ORAMED PHARMACEUTICALS INC..
“On March 12, 2024, Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Yehuda Reznick to serve as a director, effective as of April 1, 2024, to fill an existing vacancy on the board of directors (the “Board”).”
ORAMED PHARMACEUTICALS INC. terminated Controlled Equity Offering Agreement with Cantor Fitzgerald & Co. valued at Terminated with no penalties; prior net proceeds of $26.25 million (effective 2024-03-17).
“On March 12, 2024, the Company delivered written notice to Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) to terminate that certain Controlled Equity Offering Agreement, dated September 1, 2021, by and between the Company and Cantor Fitzgerald (the “Cantor Agreement”), effective as of March 17, 2024.”
ORAMED PHARMACEUTICALS INC. entered into ATM Agreement with Rodman & Renshaw LLC and StockBlock Securities LLC valued at $75,000,000 maximum aggregate offering price (effective 2024-03-18).
“On March 18, 2024, Oramed Pharmaceuticals Inc. (the “Company”) entered into an at the market offering agreement (the “ATM Agreement”) with Rodman & Renshaw LLC and StockBlock Securities LLC as sales agents (each, an “Agent” and together, the “Agents”), pursuant to which the Company may issue and sell in transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), shares of its common stock, par value $0.012 per share, having a maximum aggregate offering price of up to $75,000,000 from time to time through the Agents.”
ORAMED PHARMACEUTICALS INC. entered into "JV Agreement" with Hefei Tianhui Biotech Co., Ltd. and Technowl Limited valued at $70 million in cash from HTIT and $20 million from Oramed (comprised of $10 million in cash and $10 (effective 2024-01-22).
“On January 22, 2024, Oramed Pharmaceuticals Inc., a Delaware corporation (“Oramed”) and its wholly-owned subsidiary, Oramed Ltd., entered into a Joint Venture Agreement (the “JV Agreement”) with Hefei Tianhui Biotech Co., Ltd. (“HTIT Biotech”) and Technowl Limited, a wholly-owned indirect subsidiary of HTIT Biotech (“HTIT Sub,” and together with HTIT Biotech, “HTIT”), pursuant to which, subject to the terms and conditions set forth in the JV Agreement, the parties will establish a joint venture (“JV”) based on Oramed’s oral drug delivery technology.”
Yadin Rozov resigned as Director at ORAMED PHARMACEUTICALS INC..
“On January 17, 2024, Mr. Yadin Rozov, a member of the Board of Directors (the “Board”) of Oramed Pharmaceuticals Inc. (the “Company”), notified the Company of his intention to resign from the Board for personal reasons, effective immediately.”
Dr. Daniel Aghion was appointed as director at ORAMED PHARMACEUTICALS INC..
“On December 18, 2023, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024.”
ORAMED PHARMACEUTICALS INC. entered into Senior Secured Promissory Note with Scilex Holding Company valued at $101,875,000 (effective 2023-09-21).
“a Senior Secured Promissory Note due 18 months from the date of issuance in the principal amount of $101,875,000 (the “Note”)”
ORAMED PHARMACEUTICALS INC. terminated Stock Purchase Agreement with Sorrento Therapeutics, Inc. (effective 2023-09-21).
“ugust 7, 2023, Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), entered into a Stock Purchase Agreement (as subsequently amended on August 9, 2023 and August 21, 2023, the “Sorrento SPA”) with Sorrento Therapeutics, Inc.”
ORAMED PHARMACEUTICALS INC. entered into Securities Purchase Agreement with Scilex Holding Company (effective 2023-09-21).
“On September 21, 2023 (the “Closing Date”), the Company entered into, and consummated the transactions contemplated by, a Securities Purchase Agreement (the “Scilex SPA”) with Scilex and the Agent (as defined below).”
ORAMED PHARMACEUTICALS INC. amended Second Amendment to Stock Purchase Agreement with Sorrento Therapeutics, Inc. valued at Extended deadline for Sale Order; reduced number of Scilex warrants from 1,386,617 to 693,309 (publi (effective 2023-08-21).
“On August 21, 2023, the Company and Seller entered into a Second Amendment to Stock Purchase Agreement, pursuant to which the parties agreed: (i) to further extend the deadline for entry of the Sale Order from August 21, 2023 to August 25, 2023, (ii) to reduce the number of Scilex warrants included in the equity securities to be purchased and acquired by the Company as follows: (a) reducing the number of public warrants exercisable for shares of common stock of Scilex from warrants in respect of 1,386,617 shares of common stock to warrants in respect of 693,309 shares of common stock, and (b) reducing the number of private warrants exercisable for shares of common stock of Scilex from warrants in respect of 3,104,000 shares of common stock to warrants in respect of 1,552,000 shares of common stock; (iii) including an obligation on the part of Seller to serve notice of the proposed Sale Order containing the terms of the Junior DIP Compromise (as defined below) on the shareholders of Sci”
ORAMED PHARMACEUTICALS INC. entered into Stock Purchase Agreement with Sorrento Therapeutics, Inc. valued at $105,000,000 (effective 2023-08-07).
“entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”), between the Company and Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”), pursuant to which, upon the terms and subject to the conditions set forth therein, the Company will acquire certain securities of Scilex Holding Company (“Scilex”) owned by the Seller”
ORAMED PHARMACEUTICALS INC. shareholders approved Ratification of Independent Registered Public Accounting Firm for the 2023 Fiscal Year at the 2023-07-13 meeting.
“Proposal No. 2 — Ratification of Independent Registered Public Accounting Firm for the 2023 Fiscal Year. The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2023 fiscal year. The votes were as follows: For Against Abstain Broker Non-Votes 16,991,347 50,052 71,751 -”
ORAMED PHARMACEUTICALS INC. shareholders approved Re-election of Directors at the 2023-07-13 meeting.
“Proposal No. 1 — Re-election of Directors. The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows: Director Name For Against Abstain Broker Non-Votes Dr. Miriam Kidron 9,157,849 173,775 74,353 7,707,173 Nadav Kidron 9,182,326 168,225 55,426 7,707,173 Dr. Arie Mayer 8,920,370 438,226 47,381 7,707,173 Yadin Rozov 8,949,343 411,701 44,933 7,707,173 Leonard Sank 8,696,513 654,931 54,533 7,707,173 Benjamin Shapiro 9,239,878 120,124 45,975 7,707,173”
Benjamin Shapiro was appointed as Director at ORAMED PHARMACEUTICALS INC..
“On April 27, 2023, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Mr. Benjamin Shapiro to serve as a director to fill the resulting vacancy, effective as of May 1, 2023.”
ORAMED PHARMACEUTICALS INC.: Adopted Fourth Amended and Restated By-laws implementing rules for stockholder action by written consent, eliminating outdated provisions, limiting indemnification, and requiring majority vote for amendments (effective 2023-02-23).
“On February 23, 2023, the board of directors of Oramed Pharmaceuticals Inc. (the “Company”) adopted Fourth Amended and Restated By-laws (the “By-laws”), which became effective immediately”
ORAMED PHARMACEUTICALS INC. reported the quarter ended September 30, 2022 results: EPS $0.18.
“Basic and diluted loss per share of common stock for the three month period ended September 30, 2022 decreased by 14% to $0.18, compared to $0.21 for the three month period ended September 30, 2021.”
Yadin Rozov was appointed as director at ORAMED PHARMACEUTICALS INC..
“On March 30, 2022, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Mr. Yadin Rozov to serve as a director to fill the resulting vacancy, effective as of April 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.